FMP

FMP

Enter

DMTK - DermTech, Inc.

Profile of DermTech, Inc.(DMTK), DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tes

About

ceo

Mr. Bret Christensen

sector

Healthcare

industry

Diagnostics & Research

website

https://www.dermtech.com

exchange

NASDAQ

Description

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

CIK

0001651944

ISIN

US24984K1051

CUSIP

24984K105

Address

11099 North Torrey Pines Road

Phone

858 450 4222

Country

US

Employee

206

IPO Date

Aug 10, 2017

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep